AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12711947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10750003 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with 0.25% bupivacaine
Number of subjects: 61
Study 10750003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 61
Study 10750003 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 61
Study 8941480 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 12
Study 8941480 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 12
Study 1524913 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin (1 g/day)
Number of subjects: 230
Study 1524913 — intervention group
Group type: COMPARATOR
Intervention: co‐trimoxazole (1920 mg/day) plus colistin (800 mg/day)
Number of subjects: 230
Study 3516703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol (50 mg intravenous injection followed by 2.5 mg min‐1 infusion)
Number of subjects: 30
Study 3516703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (75 mg injection followed by 3 mg min‐1 infusion)
Number of subjects: 30
Study 3516703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29686027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 3977
Study 29686027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3977
Study 27257049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST)
Number of subjects: 517
Study 27257049 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant Therapy (CT)
Number of subjects: 517
Study 27257049 — intervention group
Group type: COMPARATOR
Intervention: Triple Therapy (TT)
Number of subjects: 517
Study 24102806 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cord blood infusion
Number of subjects: 17
Study 22524329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 62
Study 22524329 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity laser
Number of subjects: 62
Study 20884874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (>18 hours)
Number of subjects: 0
Study 20884874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (bile acid-binding resin)
Number of subjects: 0
Study 20884874 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (increased during fasting)
Number of subjects: 0
Study 20884874 — intervention group
Group type: COMPARATOR
Intervention: Diurnal rhythm of PCSK9
Number of subjects: 0
Study 18559469 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency microtenotomy
Number of subjects: 24
Study 18559469 — intervention group
Group type: COMPARATOR
Intervention: Extensor tendon release and repair
Number of subjects: 24
Study 18559469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 18559469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic infrared thermography (DIRT)
Number of subjects: 24
Study 18559469 — intervention group
Group type: EXPERIMENTAL
Intervention: DIRT
Number of subjects: 24
Study 16756147 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF)
Number of subjects: 0
Study 16756147 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 12548215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiotocography plus ST analysis
Number of subjects: 4966
Study 12548215 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography only
Number of subjects: 4966
Study 10486390 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (INFbeta-1a) 22 microg
Number of subjects: 0
Study 10486390 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (INFbeta-1a) 44 microg
Number of subjects: 0
Study 8898485 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional therapists
Number of subjects: 0
Study 8898485 — intervention group
Group type: COMPARATOR
Intervention: Nonprofessional therapists
Number of subjects: 0
Study 1505413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone-pyrimethamine (50-100 mg dapsone and 6.25-12.5 mg pyrimethamine weekly)
Number of subjects: 166
Study 1505413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 6415016 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 5) ran at their highest tolerable volitional intensity for 20‐45 min during the recovery period
Number of subjects: 10
Study 6415016 — intervention group
Group type: COMPARATOR
Intervention: Rest group (n = 5) performed no physical activity
Number of subjects: 10
Study 6415016 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 5)
Number of subjects: 10
Study 6415016 — intervention group
Group type: COMPARATOR
Intervention: Rest group (n = 5)
Number of subjects: 10
Study 29987705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 360° prophylactic endolaser photocoagulation (Group A)
Number of subjects: 50
Study 29987705 — intervention group
Group type: COMPARATOR
Intervention: Endolaser only to the retinal breaks (Group B)
Number of subjects: 50
Study 30532180 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanticipated questions regarding planning of a task
Number of subjects: 0
Study 30532180 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanticipated questions regarding spatial and temporal details
Number of subjects: 0
Study 30532180 — intervention group
Group type: EXPERIMENTAL
Intervention: Unanticipated questions technique overall
Number of subjects: 0
Study 27406897 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary surgery (specific intervention details not provided)
Number of subjects: 0
Study 27406897 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy alone (control group)
Number of subjects: 0
Study 24192055 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-pemetrexed (CPx)
Number of subjects: 132
Study 24192055 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-vinorelbine (CVb)
Number of subjects: 132
Study 24192055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 132
Study 23213757 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre plus labyrinthine sedative (Betahistine mesilate, flunarizine hydrochloride, Ginkgo biloba)
Number of subjects: 84
Study 23213757 — intervention group
Group type: COMPARATOR
Intervention: Epley's manoeuvre alone
Number of subjects: 84
Study 20849630 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention (8 sessions of 90 minutes in groups)
Number of subjects: 150
Study 20849630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 18206038 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive group (n = 26)
Number of subjects: 54
Study 18206038 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group (n = 28)
Number of subjects: 54
Study 18206038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 16366235 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint symbolic dynamics (JSD) analysis of heart rate and blood pressure in DCM
Number of subjects: 75
Study 16366235 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls, n = 75
Number of subjects: 75
Study 14658377 — intervention group
Group type: EXPERIMENTAL
Intervention: American pitchers
Number of subjects: 19
Study 14658377 — intervention group
Group type: COMPARATOR
Intervention: Korean pitchers
Number of subjects: 19
Study 9476744 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day
Number of subjects: 0
Study 9476744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 8
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 4 g twice daily
Number of subjects: 8
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and cholestyramine
Number of subjects: 8
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 8
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 8
Study 8549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and cholestyramine
Number of subjects: 8
Study 2171630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 47
Study 2171630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 42976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth and throat disinfectant lozenges (sugar-containing)
Number of subjects: 10
Study 42976 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free mouth and throat disinfectant lozenge
Number of subjects: 10
Study 31552551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg single dose, 10 mg and 20 mg multiple daily doses)
Number of subjects: 186
Study 31552551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 186
Study 28373452 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE using drug-eluting beads (DEBs) loaded with doxorubicin
Number of subjects: 127
Study 28373452 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE using polyethylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin
Number of subjects: 127
Study 25812465 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational plus interactive text message reminders
Number of subjects: 5462
Study 25812465 — intervention group
Group type: COMPARATOR
Intervention: Educational‐only text message reminders
Number of subjects: 5462
Study 25812465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5462
Study 23900878 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan (1-30 mg)
Number of subjects: 32
Study 23900878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22338349 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological skills training (PST)
Number of subjects: 65
Study 22338349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training beyond normal curriculum)
Number of subjects: 65
Study 19815198 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycles with hCG
Number of subjects: 0
Study 19815198 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation cycles
Number of subjects: 0
Study 17493004 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., pantoprazole 20 mg b.i.d.
Number of subjects: 25
Study 15833589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.5 mg/kg)
Number of subjects: 12
Study 15833589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.2 mg/kg)
Number of subjects: 12
Study 15833589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0.2 mg/kg)
Number of subjects: 12
Study 15833589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12042201 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine (10 mg/day olanzapine, 20 mg/day fluoxetine)
Number of subjects: 30
Study 12042201 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo (10 mg/day olanzapine, placebo)
Number of subjects: 30
Study 9701717 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical intolerance (CI) group
Number of subjects: 35
Study 9701717 — intervention group
Group type: COMPARATOR
Intervention: Depressives without CI group
Number of subjects: 35
Study 9701717 — intervention group
Group type: COMPARATOR
Intervention: Normals group
Number of subjects: 35
Study 7701171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 10
Study 2652217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CMT) 400 mg/night
Number of subjects: 60
Study 2652217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (RNT) 150 mg/night
Number of subjects: 60
Study 2652217 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (CMT)
Number of subjects: 60
Study 2652217 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (RNT)
Number of subjects: 60
Study 1100308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular phenytoin
Number of subjects: 12
Study 1100308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin
Number of subjects: 12
Study 31706719 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene signature (MammaPrint®)
Number of subjects: 3
Study 31706719 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene Recurrence Score (RS) assay (Oncotype DX®)
Number of subjects: 3
Study 27925359 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (AEI) for 3 months
Number of subjects: 38
Study 27925359 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received WCRF/AICR recommendations to be physically active
Number of subjects: 38
Study 28191694 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT sample treatment effects (weighted)
Number of subjects: 3592
Study 26517756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% DHEA (prasterone)
Number of subjects: 66
Study 26517756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23339050 — intervention group
Group type: EXPERIMENTAL
Intervention: NYU Caregiver Intervention (NYUCI‐AC)
Number of subjects: 107
Study 23339050 — intervention group
Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 107
Study 21174209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 0
Study 21174209 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 0
Study 18806550 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E, played in the game; n = 14)
Number of subjects: 24
Study 18806550 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, did not participate in the game; n = 10)
Number of subjects: 24
Study 18806550 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E)
Number of subjects: 24
Study 16800989 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyao Nose Drops (XYND)
Number of subjects: 126
Study 16800989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 12499043 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial cerebellar rTMS
Number of subjects: 0
Study 12499043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10827334 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-implant group
Number of subjects: 120
Study 10827334 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-implant group
Number of subjects: 120
Study 10827334 — intervention group
Group type: COMPARATOR
Intervention: Nestorone(R) implants
Number of subjects: 120
Study 8624759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumocystis carinii pneumonia (PCP)
Number of subjects: 1530
Study 8624759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium avium complex (MAC)
Number of subjects: 1530
Study 8624759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV)
Number of subjects: 1530
Study 8624759 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic mycosis
Number of subjects: 1530
Study 1411840 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom Skills
Number of subjects: 903
Study 1411840 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Influences
Number of subjects: 903
Study 1411840 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution
Number of subjects: 903
Study 1411840 — intervention group
Group type: COMPARATOR
Intervention: Control (male subjects)
Number of subjects: 903
Study 1411840 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Influences (female patients)
Number of subjects: 903
Study 6226224 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine with placebo
Number of subjects: 21
Study 6226224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine with ipratropium bromide (72 micrograms)
Number of subjects: 21
Study 30957981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency dTMS (18 Hz)
Number of subjects: 33
Study 30957981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency dTMS (1 Hz)
Number of subjects: 33
Study 30957981 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 33
Study 29500848 — intervention group
Group type: EXPERIMENTAL
Intervention: High UFP-emitting acrylonitrile butadiene styrene (ABS)
Number of subjects: 26
Study 29500848 — intervention group
Group type: COMPARATOR
Intervention: Low-emitting polylactic acid (PLA)
Number of subjects: 26
Study 26916733 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216 (5, 10, 20, 30, and 40 mg/kg) infused over 2 hours
Number of subjects: 0
Study 26916733 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216 (high doses)
Number of subjects: 0
Study 26916733 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216
Number of subjects: 0
Study 24441216 — intervention group
Group type: COMPARATOR
Intervention: Metronome
Number of subjects: 23
Study 24441216 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous music
Number of subjects: 23
Study 24441216 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous music
Number of subjects: 23
Study 22331147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 3 monthly injections of 1.25 mg
Number of subjects: 86
Study 22331147 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 injections of 2 mg 2 months apart
Number of subjects: 86
Study 22331147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 86
Study 22331147 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT)
Number of subjects: 86
Study 20204916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 44
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical method (IPLC/FLD)
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample preparation (liquid‐liquid extraction)
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocratic ion pair elution
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence detection
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Large sample volume (250 microL)
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear response
Number of subjects: 0
Study 17497754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low limits of quantification (LLOQ)
Number of subjects: 0
Study 16198881 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical long-axis (APLAX) view
Number of subjects: 100
Study 16198881 — intervention group
Group type: COMPARATOR
Intervention: Two-chamber (2CH) view
Number of subjects: 100
Study 11862975 — intervention group
Group type: COMPARATOR
Intervention: Chronic alacepril treatment (12 weeks)
Number of subjects: 4
Study 11862975 — intervention group
Group type: COMPARATOR
Intervention: Acute alacepril treatment
Number of subjects: 4
Study 10416313 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 25
Study 7554760 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (10 g, systemic infusion, n = 5)
Number of subjects: 28
Study 7554760 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine (10 g, systemic infusion, n = 3)
Number of subjects: 28
Study 7554760 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (40 mumol/l, forearm vascular bed infusion)
Number of subjects: 28
Study 7554760 — intervention group
Group type: COMPARATOR
Intervention: D-arginine (40 mumol/l, forearm vascular bed infusion)
Number of subjects: 28
Study 2371950 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic AV filling
Number of subjects: 12
Study 2371950 — intervention group
Group type: COMPARATOR
Intervention: Nonphysiologic AV filling
Number of subjects: 12
Study 7015495 — intervention group
Group type: EXPERIMENTAL
Intervention: SP + AC (sulfinpyrazone + acenocoumarol)
Number of subjects: 22
Study 7015495 — intervention group
Group type: COMPARATOR
Intervention: Placebo + AC (placebo + acenocoumarol)
Number of subjects: 22
Study 30815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory group
Number of subjects: 65
Study 30815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 65
Study 30815708 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 65
Study 30543339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard-of-care treatment beyond disease progression
Number of subjects: 0
Study 30543339 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 0
Study 26854355 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-module group treatment (cognitive, exposure, skills) for PTSD
Number of subjects: 86
Study 26854355 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) condition
Number of subjects: 86
Study 24331988 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic apex locator
Number of subjects: 220
Study 24331988 — intervention group
Group type: COMPARATOR
Intervention: Digital radiography
Number of subjects: 220
Study 22919989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Tacrolimus ointment twice a day
Number of subjects: 21
Study 22919989 — intervention group
Group type: COMPARATOR
Intervention: 0.05% Clobetasol propionate ointment once a day
Number of subjects: 21
Study 20090326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar + 1.0% (w/w) CPP‐ACP
Number of subjects: 24
Study 20090326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar + 0.5% (w/w) CPP‐ACP
Number of subjects: 24